Tego Science has received approval from the Ministry of Food and Drug Safety to initiate a Phase 1 clinical trial for TPX-121, an allogeneic cell therapy aimed at improving nasolabial folds. 

TPX-121 is an allogeneic version of "Rosmir," an autologous cell therapy that recently completed Phase 3 trials.

The Phase 1 trial will involve 18 patients to assess the safety of a single intradermal injection for moderate to severe nasolabial folds. 

While autologous therapies use the patient's own cells, reducing side effects and immune rejection risks, allogeneic therapies like TPX-121 allow for large-scale production and commercialization.

TPX-121 is Tego Science's third allogeneic cell therapy, following the previously approved "Kaloderm" and ongoing trials for "TPX-115." 

The company aims to become the first to introduce a global allogeneic wrinkle treatment, targeting the $13 billion global facial aesthetics market.